LPL Financial LLC Acquires 24,032 Shares of Tempus AI, Inc. (NASDAQ:TEM)

LPL Financial LLC boosted its stake in shares of Tempus AI, Inc. (NASDAQ:TEM) by 120.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 44,006 shares of the company’s stock after acquiring an additional 24,032 shares during the quarter. LPL Financial LLC’s holdings in Tempus AI were worth $1,486,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in TEM. Victory Capital Management Inc. bought a new position in Tempus AI in the 4th quarter worth about $216,000. China Universal Asset Management Co. Ltd. bought a new position in Tempus AI in the fourth quarter worth approximately $1,091,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in Tempus AI during the 4th quarter worth $178,000. abrdn plc bought a new stake in Tempus AI during the 4th quarter valued at $2,784,000. Finally, Dakota Wealth Management lifted its holdings in shares of Tempus AI by 189.7% in the 4th quarter. Dakota Wealth Management now owns 60,668 shares of the company’s stock worth $2,048,000 after buying an additional 39,724 shares during the period. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Tempus AI Trading Down 1.1 %

NASDAQ:TEM opened at $40.42 on Friday. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. The stock’s fifty day moving average is $54.10 and its two-hundred day moving average is $50.60. Tempus AI, Inc. has a 52 week low of $22.89 and a 52 week high of $91.45.

Insiders Place Their Bets

In other news, EVP Andrew Polovin sold 13,135 shares of the firm’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $45.98, for a total transaction of $603,947.30. Following the transaction, the executive vice president now directly owns 154,171 shares in the company, valued at approximately $7,088,782.58. This trade represents a 7.85 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Wayne A.I. Frederick sold 3,000 shares of the company’s stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $45.54, for a total transaction of $136,620.00. Following the completion of the sale, the director now directly owns 26,514 shares of the company’s stock, valued at $1,207,447.56. The trade was a 10.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,146,249 shares of company stock valued at $301,185,058 in the last ninety days.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Wolfe Research downgraded Tempus AI from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 26th. Needham & Company LLC restated a “buy” rating and set a $70.00 price objective on shares of Tempus AI in a report on Thursday, April 10th. TD Cowen reaffirmed a “buy” rating and issued a $74.00 price objective (up from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. Bank of America boosted their target price on shares of Tempus AI from $54.00 to $60.00 and gave the stock a “neutral” rating in a research report on Monday, March 3rd. Finally, Loop Capital decreased their price target on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a report on Tuesday, January 14th. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $61.18.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.